Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Gains from Sales and Divestitures (2016 - 2025)

Pediatrix Medical (MD) has disclosed Gains from Sales and Divestitures for 12 consecutive years, with $987593.0 as the latest value for Q4 2024.

  • On a quarterly basis, Gains from Sales and Divestitures rose 135.84% to $987593.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $987593.0, a 135.84% increase, with the full-year FY2024 number at $987593.0, up 135.84% from a year prior.
  • Gains from Sales and Divestitures was $987593.0 for Q4 2024 at Pediatrix Medical, up from $418756.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $987593.0 in Q4 2024 to a low of $418756.0 in Q4 2023.
  • A 4-year average of $721202.2 and a median of $739230.0 in 2021 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: tumbled 42.64% in 2023, then skyrocketed 135.84% in 2024.
  • Pediatrix Medical's Gains from Sales and Divestitures stood at $748410.0 in 2021, then dropped by 2.45% to $730050.0 in 2022, then crashed by 42.64% to $418756.0 in 2023, then surged by 135.84% to $987593.0 in 2024.
  • Per Business Quant, the three most recent readings for MD's Gains from Sales and Divestitures are $987593.0 (Q4 2024), $418756.0 (Q4 2023), and $730050.0 (Q4 2022).